LS@W supports Life Sciences startups through the Venture Challenge, Expert Classes and Value Center programs. Startups that have participated in (one or more) of these programs are listed as LS@W alumni. In addition startups that have received an NGI Pre-Seed Grant, which was part of LS@W from 2007 - 2012, are listed as LS@W alumni.
The Venture Challenge is the most successful program for startups in the Life Sciences and Medical Technology. More than 25 editions of the Venture Challenge have been organised helping startups in Therapeutics, Diagnostics, Medical Devices and Enabling Technologies. Startups that have participated in the Venture Challenge and still exist are listed.
Pre-Seed Grant Alumni
In the first years of LifeSciences@Work the NGI Pre-Seed Grant was part of the program. Startups that have received a Pre-Seed Grant via the LS@W program and still exist are listed.
Incircular Biotechnologies uses its unique patented INCYPRO technology to stabilize G protein-coupled receptors (GPCRs) for reliable applications in drug discovery. This will enable the development of drug candidates for currently non-targeted GPCRs.
Our in-silico platform can simulate stent-retriever-based thrombectomy in various patient-specific scenarios of varying vascular anatomy and clot characteristics. This allows the medical device industries to evaluate the performance of their novel devices before pre-clinical testing.
The Overkleeft group at Leiden University discovered superior proteasome inhibitors, and it is the aim of iProtics to develop these leads to become the first-in-line treatment for Multiple Myeloma patients.
To develop early-stage antibiotic lead compounds discovered by researchers at Utrecht University. Specifically, we aim to target clinically-relevant pathogenic bacteria that have become resistant to first-line antibiotics.